Featured
The Actuarial Paradox: How Medicare's Metabolic Pivot is Starving the Biotech R&D Pipeline
An expert impact analysis exploring how the 2026 implementation of Medicare drug price negotiations and the CMS expansion of GLP-1 coverage are fundam...
Read Full Story →